RTA 408 Capsules in Patients With Friedreich's Ataxia

Status Active, not recruiting

Clinical Trial Summary

Friedreich's ataxia is an autosomal recessive cerebellar ataxia caused by triplet-repeat expansions. The causative mutation is a trinucleotide (GAA) repeat expansion in the first intron of the frataxin gene, leading to impaired transcription of frataxin. The pathological consequences of frataxin deficiency include a severe disruption of iron-sulfur cluster biosynthesis, mitochondrial iron overload coupled to cellular iron dysregulation, and an increased sensitivity to oxidative stress. A hallmark of Friedreich's ataxia is impairment of antioxidative defense mechanisms, which play a major role in disease progression. Studies have demonstrated that nuclear factor erythroid-derived 2-related factor 2 (Nrf2) signaling is grossly impaired in patients with Friedreich's ataxia. Therefore, the ability of omaveloxolone (RTA 408) to activate Nrf2 and induce antioxidant target genes is hypothesized to be therapeutic in patients with Friedreich's ataxia. This 2-part study will evaluate the efficacy, safety, and pharmacodynamics of omaveloxolone (RTA 408) in the treatment of patients with Friedreich's ataxia. Part 1: The first part of this study will be a randomized, placebo-controlled, double-blind, dose-escalation study to evaluate the safety of omaveloxolone (RTA 408) at various doses in patients with Friedreich's ataxia. Part 2: The second part of this study is a randomized, placebo-controlled, double-blind, parallel-group study to evaluate the safety and efficacy of omaveloxolone (RTA 408) 150 mg in patients with Friedreich's ataxia. Patients enrolled in Part 2 will be randomized 1:1 to receive omaveloxolone (RTA 408) 150 mg or placebo. Extension: The extension will assess long-term safety and tolerability of omaveloxolone (RTA 408) in qualified patients with Friedreich's ataxia following completion of Part 1 or Part 2. Patients will not be unblinded to study treatment in Part 1 or Part 2 upon entering the extension study. Patients will receive open-label omaveloxolone (RTA 408) at 150 mg once daily.

Clinical Trial Description

Study Sponsor, originally Reata Pharmaceuticals, Inc., is now Reata Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02255435
Study type	Interventional
Source	Biogen
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	January 31, 2015
Completion date	December 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05573698` - Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia	Phase 1
Completed	`NCT00229632` - Idebenone to Treat Friedreich's Ataxia	Phase 2
Completed	`NCT05579691` - A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia	Phase 2
Completed	`NCT04273165` - Safety and Efficacy of Etravirine in Friedreich Ataxia Patients	Phase 2
Not yet recruiting	`NCT05874388` - Characterisation of the Cognitive Profile of Patients Suffering From Friedreich's Ataxia	N/A
Completed	`NCT02594917` - Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension
Completed	`NCT01716221` - An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia	Phase 4
Active, not recruiting	`NCT05485987` - A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia	Phase 2
Completed	`NCT03214588` - Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia	Phase 2
Completed	`NCT03418740` - Neurology Measures in FA Children
Not yet recruiting	`NCT06054893` - A Study of Omaveloxolone in Children With Friedreich's Ataxia	Phase 1
Recruiting	`NCT04921930` - Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)	Phase 1/Phase 2
Active, not recruiting	`NCT03933163` - Micronised Resveratrol as a Treatment for Friedreich Ataxia	Phase 2
Completed	`NCT02705547` - Rosuvastatin (Crestor) in Friedreich Ataxia	Early Phase 1
Completed	`NCT02035020` - A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients	Phase 2
Completed	`NCT00015808` - Safety Study of Idebenone to Treat Friedreich's Ataxia	Phase 1
Completed	`NCT04817111` - NAD+ Precursor Supplementation in Friedreich's Ataxia	Phase 2
Active, not recruiting	`NCT05168774` - FRDA Investigator Initiated Study (IIS) With Elamipretide	Phase 1/Phase 2
Completed	`NCT03917225` - A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients	Phase 2
Completed	`NCT00224640` - Iron-Chelating Therapy and Friedreich Ataxia	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms